PD1 and PDL1 Expression in Midgut Neuroendocrine Tumors Abstract #1561

Introduction: PD1/PDL1 inhibitors have shown promising results in different carcinomas, and correlation between PDL1 expression and response to immunotherapy has been reported. No studies thus far have investigated the expression of PD1 or PDL1 in midgut NETs.
Aim(s): To investigate the expression of PD1/PDL1 in midgut NETs, and its relation to the presence of peritumoral lymphoid cell aggregates containing germinal centers (lymph node-like structures; LLS).
Materials and methods: PD1 and PDL1 expression was assessed by immunohistochemistry in 32 patients with midgut NET. All cases with moderate or strong staining by Allred score were considered positive. The presence or absence of LLS was evaluated on H/E stained sections, and characterized by immunohistochemistry.
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Dr. Mauro Cives

To read results and conclusion, please login ...

Further abstracts you may be interested in

#554 Analysis of the AJCC/ENETS Staging Classification for Midgut Neuroendocrine Tumors
Introduction: The American Joint Committee on Cancer (AJCC) and ENETS have independently introduced a novel TNM staging classification for jejunal-ileal NETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Max Feldman
#556 Unresectable Mesenteric Midgut NETs: Are They a Unique Prognostic Category?
Introduction: Patients with lymph-node positive midgut NETs (stage IIIB) represent a heterogeneous group. While some have microscopic lymph node involvement on pathological evaluation, others may develop large, desmoplastic, unresectable tumors in the root of the mesentery.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
#1181 Significance of Ectopic Lymph Node-Like Structures in Neuroendocrine Tumors of the Small Bowel
Introduction: The formation of extranodal tertiary lymphoid follicles and lymphoid cell aggregates has been described in nonmalignant conditions including autoimmune diseases and chronic inflammation as well as in cancer. Tumor-induced lymph node-like structures (LLS) participate in the host’s antitumor immune response by driving intratumoral immune cell priming
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: Dr. Mauro Cives
#1268 The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs
Introduction: Programmed death-ligand 1 (PD-L1), which is expressed on many cancer cells, interacts with PD1 expressed on the surface of T cells, inhibiting the T cells and blocking the antitumor immune response.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Seung Kim
Authors: Kim S, Park Y
Keywords: PD-L1, GEP-NETs
#1179 A Phase II Study of Axitinib in Advanced Carcinoid Tumors: Preliminary Results
Introduction: NETs are highly vascularized neoplasms overexpressing VEGF as well as VEGFR. Axitinib is a TKI with selective picomolar potency against VEGFR-1, -2 and -3
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Mauro Cives
Authors: Cives M, Strosberg J, Campos T, Weber T, ...